World Fair for Organic Wines: the Trade Fair Will Be Back Again in Force In 2022!
14.12.2021 17:07:00 EET | Business Wire | Press release
Millésime Bio has become, over the years, the number one marketplace for professionals in the organic wine, cider, beer and spirits industries. With its digital session on 17 and 18 January 2022 and its physical fair on 24, 25 and 26 January 2022 at Montpellier Exhibition Centre, the World Fair for Organic Wines will be the first major international wine fair since the COVID crisis, a symbol that the recovery is underway.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211214005696/en/
(Photo: Gilles Lefrancq/Millésime Bio)
MILLESIME BIO 2022: A DOUBLE EVENT
Millésime Bio, traditionally the first wine, cider, beer and spirits trade fair of the year, will take place in two stages for this 2022 edition. A double event that will guarantee all professionals their participation while taking into account the sanitary constraints imposed in France and abroad.
The World fair for organic wines will start on 17 January for two days. Based on the model of the 2021 100% digital edition, more than 450 exhibitors and several thousand visitors will be able to exchange information and make initial contacts prior to the physical fair. On this occasion, visitors will discover in preview the medal-winners list of the Challenge Millésime Bio 2022 contest. From Monday 24 January to Wednesday 26 January, the physical fair will be an opportunity to get back to live tastings and meetings.
12/01/2022 - CHALLENGE MILLESIME BIO 2022
Every year, SudVinBio organises the largest international organic wine contest before the fair: the Challenge Millésime Bio contest. This year, the 15th edition of the contest will take place on Wednesday 12 January 2022.
NEW: Challenge Millésime Bio is opening up to international organic beers. The contest team will be accompanied by the SNBI (French National Union for Independent Breweries) to set up this tasting.
The medal-winning wines and beers will be available for tasting during the 3 days of the fair, in an area dedicated to the Challenge Millésime Bio.
More than 1,400 exhibitors from 20 countries will be there, in the heart of the number one organic vineyard in France, and will present about 40% of the French organic wine offer and a wide range of the international offer. This renewed enthusiasm consolidates Millésime Bio's position as the key marketplace that will set the trend for future trade fairs in a post health crisis context.
In parallel with the meetings with exhibitors, visitors will be able to attend a 2-day programme of conferences and Master Classes led by experts. The programme will include the results of a European IPSOS/Millésime Bio study on organic wine consumption habits.
"The Millésime Bio trade fair will welcome you from 17 January, to start with in its digital format. Following the success of last year's launch, we have perfected our online platform this year, in order to programme it a few days before our traditional physical event, which is back at last!
More than ever, we are listening to visitors and exhibitors to optimise the efficiency of this key event for buyers in the organic wine and spirits sector. Thus, a special place is reserved this year for the brewery and cider industries.”
Jeanne Fabre, President of the Millésime Bio Commission
ABOUT
MILLÉSIME BIO IS ORGANISED BY SUDVINBIO, OCCITANIA TRADE ASSOCIATION OF ORGANIC VINTNERS
SudVinBio is a non-profit association created in 1991. It is an interprofessional organisation representing producers (independent wineries and cooperatives) and merchants of organic wines in the Occitania region, France’s number one organic wine region. SudVinBio represents around 70% of the regional production of certified organic wines at the end of 2020 (around 700 000 hl). It orchestrates promotional and communication activities, protects the interests of its members, provides support for research and development as well as advisory services to its members.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211214005696/en/
Contact information
PRESS CONTACT
Anaïs Marchand & Fanny Courtial
+33 (0)4 72 07 42 41
fanny.courtial@clairdelune.fr – www.clairdelune.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom